

Applicant: Duggan *et al.*
 Docket No: 1581.0580000/RWE/KKV
 M & S Ref. No: GWS/MRM/21094

POWER OF ATTORNEY FROM MULTIPLE ASSIGNEES

(1) Microbiological Research Authority, a Government: Special Health Authority of Great Britain, having a principal place of business at CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG and (2) The Speywood Laboratory Limited, a corporation of Great Britain, having a principal place of business at 14 Kensington Square, London W8 5HH, are, collectively, assignees of the entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), by reason of an Assignment executed to Assignee (1) on 17 April/15 May '00 and to Assignee (2) on _____ of an invention known as Conjugates of Galactose-Binding Lectins and Clostridial Neurotoxins as Analgesics (Attorney Docket No. 1581.0580000/RWE/KKV), that is disclosed and claimed in a patent application of the same title by the inventors Michael John DUGGAN, and John Andrew CHADDOCK (said application filed _____ at the U.S. Patent and Trademark Office, having Application Number to be assigned) (International Filing Date: October 7, 1998; International Appl. No. PCT/GB98/03001).

The Assignees hereby appoint the following U.S. attorneys to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith: Robert Greene Sterne, Registration No. 28,912; Edward J. Kessler, Registration No. 25,688; Jorge A. Goldstein, Registration No. 29,021; Samuel L. Fox, Registration No. 30,353; David K.S. Cornwell, Registration No. 31,944; Robert W. Esmond, Registration No. 32,893; Tracy-Gene G. Durkin, Registration No. 32,831; Michele A. Cimbala, Registration No. 33,851; Michael B. Ray, Registration No. 33,997; Robert E. Sokohl, Esquire Registration No. 36,013; Eric K. Steffe, Registration No. 36,688; Michael Q. Lee, Registration No. 35,239; Steven R. Ludwig, Registration No. 36,203; Raz E. Fleshner, Registration No. 34,331; John M. Covert, Registration No. 38,759; and Linda E. Alcorn, Registration No. 39,588. The Assignees hereby grant said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

The Assignee hereby authorizes the U.S. attorneys named herein to accept and follow instructions from Mathys & Squire

100 Gray's Inn Road, London WC1X 8AL

as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and the Assignee. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by the Assignee.

Send correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

1100 New York Avenue, N.W.

Suite 600

Washington, D.C. 20005-3934

U.S.A.

Direct phone calls to 202-371-2600.

FOR: Microbiological Research Authority

SIGNATURE: _____

BY: _____

TITLE: _____

DATE: _____

2 June 2000

Applicant: Duggan *et al.*
Docket No: 1581.0580000/RWE/KKV
M & S Ref. No: GWS/MRM/21094

FOR: The Speywood Laboratory Limited

SIGNATURE: _____

BY: _____

TITLE: _____

DATE: _____

002290" 06T62560

21094
#3

Applicant: Duggan *et al.*
Docket No: 1581.0580000/RWE/KKV
M & S Ref. No: GWS/MRM/21094

Declaration for Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled Conjugates of Galactose-Binding Lectins and Clostridial Neurotoxins as Analgesics, specification of which is attached hereto unless the following box is checked:

- ☒ was filed on October 7, 1998;
as United States Application Number or PCT International Application Number PCT/GB98/03001
was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application, which designated at least one country other than the United States listed below, and have also identified below any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)

Priority Claimed

9721189.0
(Application No.)

Great Britain
(Country)

October 8, 1997
(Day/Month/Year Filed)

☒ Yes ☐ No

(Application No.)

(Country)

(Day/Month/Year Filed)

☐ Yes ☐ No

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

(Application No.)

(Filing Date)

(Application No.)

(Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or under § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56 that became available between the filing date of the prior application and the national or PCT international filing date of this application.

(Application No.)

(Filing Date)

(Status - patented, pending, abandoned)

(Application No.)

(Filing Date)

(Status - patented, pending, abandoned)

Applicant: Duggan *et al.*
Docket No: 1581.0580000/RWE/KKV
M & S Ref. No: GWS/MRM/21094

Send Correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934

Direct Telephone Calls to:

(202) 371-2600

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor	Michael John DUGGAN
Signature of sole or first inventor	Date
Residence	London, United Kingdom
Citizenship	United Kingdom
Post Office Address	27a, Moreton Place, London, SW1V 2NL, United Kingdom
Full name of second inventor	2-00 John Andrew CHADDOCK
Signature of second inventor	X <i>[Signature]</i> X Date 17/11/00
Residence	Hampshire, United Kingdom GBX
Citizenship	United Kingdom
Post Office Address	37, Thumwood, Chichester, Basingstoke, Hampshire, RG24 8TE, United Kingdom 43 BOXERS WAY, SALISBURY, WILTS
	SP2 8RW OK

P:\USERS\skvidov\15810580000\doc
SKGF Rev. 9/2/98 mac

(Supply similar information and signature for subsequent joint inventors, if any)

21094
#3

Applicant: Duggan *et al.*
Docket No: 1581.0580000/RWE/KKV
M & S Ref. No: GWS/MRM/21094

Declaration for Patent Application

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter that is claimed and for which a patent is sought on the invention entitled Conjugates of Galactose-Binding Lectins and Clostridial Neurotoxins as Analgesics, specification of which is attached hereto unless the following box is checked:

- ☒ was filed on October 7, 1998;
as United States Application Number or PCT International Application Number PCT/GB98/03001
was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application, which designated at least one country other than the United States listed below, and have also identified below any foreign application for patent or inventor's certificate, or PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application(s)			Priority Claimed	
<u>9721189.0</u> (Application No.)	<u>Great Britain</u> (Country)	<u>October 8, 1997</u> (Day/Month/Year Filed)	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No
_____ (Application No.)	_____ (Country)	_____ (Day/Month/Year Filed)	<input type="checkbox"/> Yes	<input type="checkbox"/> No

I hereby claim the benefit under 35 U.S.C. § 119(e) of any United States provisional application(s) listed below.

_____ (Application No.)	_____ (Filing Date)
_____ (Application No.)	_____ (Filing Date)

I hereby claim the benefit under 35 U.S.C. § 120 of any United States application(s), or under § 365(c) of any PCT international application designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. § 112, I acknowledge the duty to disclose information that is material to patentability as defined in 37 C.F.R. § 1.56 that became available between the filing date of the prior application and the national or PCT international filing date of this application.

_____ (Application No.)	_____ (Filing Date)	_____ (Status - patented, pending, abandoned)
_____ (Application No.)	_____ (Filing Date)	_____ (Status - patented, pending, abandoned)

Applicant: Duggan *et al.*
Docket No: 1581.0580000/RWE/KKV
M & S Ref. No: GWS/MRM/21094

Send Correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934

Direct Telephone Calls to:

(202) 371-2600

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of sole or first inventor	1-00	Michael John DUGGAN
Signature of sole or first inventor	X	X 15 May 2000 Date
Residence		London, United Kingdom GBX
Citizenship		United Kingdom
Post Office Address		16A ST GEORGES DRIVE, LONDON SW1V 4BL 97a, Monmouth Place, London, SW1V 2NE, United Kingdom
Full name of second inventor	7	John Andrew CHADDOCK
Signature of second inventor		Date
Residence		Hampshire, United Kingdom
Citizenship		United Kingdom
Post Office Address		37, Thumbwood, Chineham, Basingstoke, Hampshire, RG24 8TE, United Kingdom

PAUSERSKvidovich15810580000.doc
SKGF Rev. 9/2/98 mac

(Supply similar information and signature for subsequent joint inventors, if any)

Applicant: Duggan et al.
Docket No: 1581.0580000/RWE/KKV
M & S Ref. No: GWS/MRM/21094

POWER OF ATTORNEY FROM MULTIPLE ASSIGNEES

(1) Microbiological Research Authority, a Government: Special Health Authority of Great Britain, having a principal place of business at CAMR, Porton Down, Salisbury, Wiltshire SP4 0JG and (2) The Speywood Laboratory Limited, a corporation of Great Britain, having a principal place of business at 14 Kensington Square, London W8 5HH, are, collectively, assignees of the entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), by reason of an Assignment executed to Assignee (1) on 17 April/15 May '00 and to Assignee (2) on _____ of an invention known as Conjugates of Galactose-Binding Lectins and Clostridial Neurotoxins as Analgesics (Attorney Docket No. 1581.0580000/RWE/KKV), that is disclosed and claimed in a patent application of the same title by the inventors Michael John DUGGAN, and John Andrew CHADDOCK (said application filed _____ at the U.S. Patent and Trademark Office, having Application Number to be assigned) (International Filing Date: October 7, 1998; International Appl. No. PCT/GB98/03001).

The Assignees hereby appoint the following U.S. attorneys to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith: Robert Greene Sterne, Registration No. 28,912; Edward J. Kessler, Registration No. 25,688; Jorge A. Goldstein, Registration No. 29,021; Samuel L. Fox, Registration No. 30,353; David K.S. Cornwell, Registration No. 31,944; Robert W. Esmond, Registration No. 32,893; Tracy-Gene G. Durkin, Registration No. 32,831; Michele A. Cimbala, Registration No. 33,851; Michael B. Ray, Registration No. 33,997; Robert E. Sokohl, Esquire Registration No. 36,013; Eric K. Steffe, Registration No. 36,688; Michael Q. Lee, Registration No. 35,239; Steven R. Ludwig, Registration No. 36,203; Raz E. Fleshner, Registration No. 34,331; John M. Covert, Registration No. 38,759; and Linda E. Alcorn, Registration No. 39,588. The Assignees hereby grant said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

The Assignee hereby authorizes the U.S. attorneys named herein to accept and follow instructions from Mathys & Squire
100 Gray's Inn Road, London WCIX 8AL

as to any action to be taken in the U.S. Patent and Trademark Office regarding this application without direct communication between the U.S. attorneys and the Assignee. In the event of a change in the persons from whom instructions may be taken, the U.S. attorneys named herein will be so notified by the Assignee.

Send correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
U.S.A.

Direct phone calls to 202-371-2600.

FOR: Microbiological Research Authority

SIGNATURE: _____


BY: _____

TITLE: _____

DATE: _____

Applicant: Duggan *et al.*
Docket No: 1581.0580000/RWE/KKV
M & S Ref. No: GWS/MRM/21094

FOR: The Speywood Laboratory Limited

SIGNATURE: 

BY: John Charles DAVIS

TITLE: Company Secretary

DATE: 2 June 2000

Applicant: Duggan *et al.*
 Docket No: 1581.0580000/RWE/KKV
 M & S Ref. No: GWS/MRM/21094

Certificate Under 37 C.F.R. § 3.73(b)

Applicant/Patent Owner: Michael John DUGGAN, John Andrew CHADDOCK

Int'l. Appl. No: PCT/GB98/03001 Filed/Issue Date: October 7, 1998

Entitled: Conjugates of Galactose-Binding Lectins and Clostridial Neurotoxins as Analgesics

The Speywood Laboratory Limited, a corporation

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☐ the assignee of the entire right, title, and interest, or
2. ☒ an assignee of an undivided part interest

in the patent application/patent identified above by virtue of either:

- A. ☒ An Assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s) of the patent application/patent identified above to the current assignee as shown below:

1. From: _____ To: _____
 The document was recorded in the Patent and Trademark Office at
 Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
 The document was recorded in the Patent and Trademark Office at
 Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
 The document was recorded in the Patent and Trademark Office at
 Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (*i.e.*, the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302-302.8]

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

Date: 2 June '2000

Name: John Charles DAVIS

Title: Company Secretary

Signature: J Davis

Applicant: Duggan *et al.*
Docket No: 1581.0580000/RWE/KKV
M & S Ref. No: GWS/MRM/21094

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventor(s): Michael John DUGGAN, John Andrew CHADDOCK, the undersigned inventor(s) hereby sell(s) and assign(s) to Microbiological Research Authority and The Speywood Laboratory Limited (the Assignees) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages:

check applicable box(es) ☒ for the United States of America (as defined in 35 U.S.C. § 100),
☒ and throughout the world,

(a) in the invention(s) known as Conjugates of Galactose-Binding Lectins and Clostridial Neurotoxins as Analgesics for which application(s) for patent in the United States of America has (have) been executed by the undersigned on 17/4/00 (also known as International Application No. PCT/GB98/03001, filed October 7, 1998), in any and all applications thereon, in any and all Letters Patent(s) therefor, and X

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with the application(s) and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.


The undersigned inventor(s) hereby represent(s) that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

Applicant: Duggan *et al.*
Docket No: 1581.0580000/RWE/KKV
M & S Ref. No: GWS/MRM/21094

The undersigned inventor(s) hereby grant(s) Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; Samuel L. Fox, Esquire, Registration No. 30,353; David K.S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michele A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; Raz E. Fleshner, Esquire, Registration No. 34,331; John M. Covert, Esquire, Registration No. 38,759; and Linda E. Alcorn, Esquire, Registration No. 39,588; all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventor(s) on the date opposite his/her name.

Date: _____ Signature of Inventor: _____
Michael John DUGGAN

Date: 17/4/00 Signature of Inventor:  X
John Andrew CHADDOCK

DO NOT FORWARD
TO ASSIGNMENT BRANCH
NOT FOR RECORDATION

Applicant: Duggan et al.
Docket No: 1581.0580000/RWE/KKV
M & S Ref. No: GWS/MRM/21094

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventor(s): Michael John DUGGAN, John Andrew CHADDOCK, the undersigned inventor(s) hereby sell(s) and assign(s) to Microbiological Research Authority and The Speywood Laboratory Limited (the Assignees) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages:

check applicable box(es) ☒ for the United States of America (as defined in 35 U.S.C. § 100),
☒ and throughout the world,

(a) in the invention(s) known as Conjugates of Galactose-Binding Lectins and Clostridial Neurotoxins as Analgesics for which application(s) for patent in the United States of America has (have) been executed by the undersigned on 15 May 2000 (also known as International Application No. PCT/GB98/03001, filed October 7, 1998), in any and all applications thereon, in any and all Letters Patent(s) therefor, and X

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with the application(s) and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.


The undersigned inventor(s) agree(s) to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventor(s) hereby represent(s) that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

Applicant: Duggan *et al.*
Docket No: 1581.0580000/RWE/KKV
M & S Ref. No: GWS/MRM/21094

The undersigned inventor(s) hereby grant(s) Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; Samuel L. Fox, Esquire, Registration No. 30,353; David K.S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michele A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; Raz E. Fleshner, Esquire, Registration No. 34,331; John M. Covert, Esquire, Registration No. 38,759; and Linda E. Alcorn, Esquire, Registration No. 39,588; all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventor(s) on the date opposite his/her name.

Date: X 15 May 2000 Signature of Inventor: X 
Michael John DUGGAN

Date: _____ Signature of Inventor: _____
John Andrew CHADDOCK

DO NOT FORWARD
TO ASSIGNMENT BRANCH
NOT FOR RECORDATION

21094 #3
PTO/PCT Rec'd 22 JUN 2000

Applicant: Duggan *et al.*
Docket No: 1581.0580000/RWE/KKV
M & S Ref. No: GWS/MRM/21094

Certificate Under 37 C.F.R. § 3.73(b)

Applicant/Patent Owner: Michael John DUGGAN, John Andrew CHADDOCK

Application No./Patent No.: Int'l. Appl. No. PCT/GB98/03001 Filed/Issue Date: October 7, 1998

Entitled: Conjugates of Galactose-Binding Lectins and Clostridial Neurotoxins as Analgesics

Microbiological Research Authority, a Government: Special Health Authority

(Name of Assignee)

(Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☐ the assignee of the entire right, title, and interest, or
2. ☒ an assignee of an undivided part interest

in the patent application/patent identified above by virtue of either:

- A. ☒ An Assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the Patent and Trademark Office at Reel _____, Frame _____, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s) of the patent application/patent identified above to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (*i.e.*, the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302-302.8]

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

Date: 2 June 2000

Name: Jim HARKER

Title: SECRETARY MRA (CAME)

Signature: [Signature]

Applicant: Duggan et al.
Docket No: 1581.0580000/RWE/KKV
M & S Ref. No: GWS/MRM/21094

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventor(s): Michael John DUGGAN, John Andrew CHADDOCK, the undersigned inventor(s) hereby sell(s) and assign(s) to Microbiological Research Authority and The Speywood Laboratory Limited (the Assignees) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages:

check applicable box(es) ☒ for the United States of America (as defined in 35 U.S.C. § 100),
☒ and throughout the world,

(a) in the invention(s) known as Conjugates of Galactose-Binding Lectins and Clostridial Neurotoxins as Analgesics for which application(s) for patent in the United States of America has (have) been executed by the undersigned on 17/4/00 (also known as International Application No. PCT/GB98/03001, filed October 7, 1998), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with the application(s) and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventor(s) hereby represent(s) that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

Applicant: Duggan *et al.*
Docket No: 1581.0580000/RWE/KKV
M & S Ref. No: GWS/MRM/21094

The undersigned inventor(s) hereby grant(s) Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; Samuel L. Fox, Esquire, Registration No. 30,353; David K.S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michele A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; Raz E. Fleshner, Esquire, Registration No. 34,331; John M. Covert, Esquire, Registration No. 38,759; and Linda E. Alcorn, Esquire, Registration No. 39,588; all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventor(s) on the date opposite his/her name.

Date: _____ Signature of Inventor: _____
Michael John DUGGAN

Date: X 17/4/00 Signature of Inventor: *John Andrew Chaddock* X
John Andrew CHADDOCK

DO NOT FORWARD
TO ASSIGNMENT BRANCH
NOT FOR RECORDATION

Applicant: Duggan et al.
Docket No: 1581.0580000/RWE/KKV
M & S Ref. No: GWS/MRM/21094

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventor(s): Michael John DUGGAN, John Andrew CHADDOCK, the undersigned inventor(s) hereby sell(s) and assign(s) to Microbiological Research Authority and The Speywood Laboratory Limited (the Assignees) his/her entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages:

check applicable box(es) ☒ for the United States of America (as defined in 35 U.S.C. § 100),
☒ and throughout the world,

(a) in the invention(s) known as Conjugates of Galactose-Binding Lectins and Clostridial Neurotoxins as Analgesics for which application(s) for patent in the United States of America has (have) been executed by the undersigned on 15 May 2000 (also known as International Application No. PCT/GB98/03001, filed October 7, 1998), in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventor(s) agree(s) to execute all papers necessary in connection with the application(s) and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.


The undersigned inventor(s) agree(s) to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventor(s) hereby represent(s) that he/she has full right to convey the entire interest herein assigned, and that he/she has not executed, and will not execute, any agreement in conflict therewith.

Applicant: Duggan *et al.*
Docket No: 1581.0580000/RWE/KKV
M & S Ref. No: GWS/MRM/21094

The undersigned inventor(s) hereby grant(s) Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; Samuel L. Fox, Esquire, Registration No. 30,353; David K.S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michele A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; Raz E. Fleshner, Esquire, Registration No. 34,331; John M. Covert, Esquire, Registration No. 38,759; and Linda E. Alcorn, Esquire, Registration No. 39,588; all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventor(s) on the date opposite his/her name.

Date: X 15 May 2000 Signature of Inventor: X 
Michael John DUGGAN

Date: _____ Signature of Inventor: _____
John Andrew CHADDOCK

DO NOT FORWARD
TO ASSIGNMENT BRANCH
NOT FOR RECORDATION